Andrew W. Roberts

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Erwin R. Boghaert, Scott Ackler et al. · Nature Medicine · 2013 · 2.9K citations

Thrombopoiesis, Thrombosis, Hematological Malignancy +11

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.8K citations · Full text

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

Mark F. van Delft, Andrew H. Wei, Kylie D. Mason et al. · Cancer Cell · 2006 · 1.2K citations · Full text

Apoptosis, Immunology, Cell Death +4

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1K citations

Mcl1 Inhibitor S63845, Systems Biology, Oncology +11

Programmed Anuclear Cell Death Delimits Platelet Life Span

Kylie D. Mason, Marina R. Carpinelli, Jamie I. Fletcher et al. · Cell · 2007 · 1K citations · Full text

Thrombopoiesis, Blood Platelet, Hematology +4